Capecitabine is an oral fluoropyrimidine prodrug that undergoes stepwise enzymatic conversion to 5-fluorouracil preferentially within tumour tissue, used for colorectal and breast cancer. Simson Pharma's Capecitabine reference standard and impurities support the demanding stability-indicating QC this pro-drug oncology agent requires.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Capecitabine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.